CHS 828 inhibits neuroblastoma growth in mice alone and in combination with antiangiogenic drugs.
about
Recent developments in antiangiogenic therapy.NF-kappa B as a target for cancer therapy.Regression of orthotopic neuroblastoma in mice by targeting the endothelial and tumor cell compartmentsRadionuclide therapy via SSTR: future aspects from experimental animal studies.The anti-VEGF antibody bevacizumab potently reduces the growth rate of high-risk neuroblastoma xenografts.Metronomic administration of the drug GMX1777, a cellular NAD synthesis inhibitor, results in neuroblastoma regression and vessel maturation without inducing drug resistance.
P2860
CHS 828 inhibits neuroblastoma growth in mice alone and in combination with antiangiogenic drugs.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
CHS 828 inhibits neuroblastoma ...... ion with antiangiogenic drugs.
@en
CHS 828 inhibits neuroblastoma ...... ion with antiangiogenic drugs.
@nl
type
label
CHS 828 inhibits neuroblastoma ...... ion with antiangiogenic drugs.
@en
CHS 828 inhibits neuroblastoma ...... ion with antiangiogenic drugs.
@nl
prefLabel
CHS 828 inhibits neuroblastoma ...... ion with antiangiogenic drugs.
@en
CHS 828 inhibits neuroblastoma ...... ion with antiangiogenic drugs.
@nl
P2093
P2860
P1433
P1476
CHS 828 inhibits neuroblastoma ...... ion with antiangiogenic drugs.
@en
P2093
Asa Svensson
Elin Jonsson
Rolf Christofferson
Rolf Larsson
Ulrika Bäckman
P2860
P304
P356
10.1203/00006450-200205000-00011
P407
P577
2002-05-01T00:00:00Z
P5875
P6179
1019540076